Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12602739 | 0.93 | PAOX (0.59) | PAOXCYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL23344402 | 0.93 | — | — | |
| SCHEMBL11523231 | 0.86 | PAOX (0.85) | PAOXCYP1A2TDP1TP53LMNA | |
| SCHEMBL12412655 | 0.85 | PAOX (0.96) | PAOXCYP1A2TDP1ALDH1A1POLB | |
| SCHEMBL14622532 | 0.84 | PAOX (0.52) | PAOXMAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL22821442 | 0.84 | GLA (0.55) | PAOXCYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL13993971 | 0.83 | — | — | |
| SCHEMBL11880993 | 0.83 | ALDH1A1 (0.60) | PAOXCYP1A2TP53MAPTLMNA | |
| SCHEMBL13589531 | 0.82 | CYP1A2 (0.54) | PAOXCYP1A2TDP1ALDH1A1 | |
| SCHEMBL18361097 | 0.82 | PAOX (0.50) | PAOXMAPTLMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3497094-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| EP-3494155-A1 | TWO-COMPONENT POLYURETHANE ADHESIVE HAVING SUBSTANTIALLY TEMPERATURE-INDEPENDENT MECHANICAL PROPERTIES AND HIGH STRENGTH | Sika Technology AG (CH) | 2019-06-12 | — | — | EP | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| WO-2018031434-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018024626-A1 | TWO-COMPONENT POLYURETHANE ADHESIVE HAVING SUBSTANTIALLY TEMPERATURE-INDEPENDENT MECHANICAL PROPERTIES AND HIGH STRENGTH | SIKA TECHNOLOGY AG (CH) | 2018-02-08 | — | — | WO | disclosed |
| US-9745335-B2 | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application | BLIRT S.A. (PL) | 2017-08-29 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | MEDLOGICS DEVICE CORPORATION (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | MEDLOGICS DEVICE CORPORATION (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | PAOX 789/4885CYP1A2 3911/4885TDP1 65/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | PAOX 2984/4885CYP1A2 4232/4885TDP1 1709/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | PAOX 3326/4885CYP1A2 3426/4885TDP1 1402/4885 |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | CAD, DBNL, DCAF15 | PAOX 4485/4885CYP1A2 4827/4885TDP1 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.